pediatric endocrinology Archive

William Russell, MD, second from right, is the principal investigator for a study that uses a plasmid-based therapy to try to selectively desensitize the immune system in people with Type 1 diabetes. Shown here are, from left, Lana Howard, RN, CCRP; Brenna Hammel, RN, CPN; study participant Adam Brooks; Russell; and Robin Perkins, RN. Not pictured: Faith Brendle, RN, CPN, CCRP.
September 1, 2022

Trial participant steps up to help advance diabetes research

Vanderbilt is one of 16 North American sites conducting the Tolerance Using Plasmid in People with Type 1 Diabetes (TOPPLE) study, a phase 1 investigation that tests the safety and dosing of a new plasmid therapy.

By Jill Clendening
February 10, 2022

New insights into hypothalamic obesity

A common Type 2 diabetes treatment being tested for hypothalamic obesity had unexpected results on weight loss and total energy expenditure, Vanderbilt researchers report.

By VUMC News and Communications
September 16, 2021

‘Pre-conditioning’ restores immune tolerance

A treatment targeting T-cell metabolism could reinvigorate immune tolerance mechanisms to combat autoimmune disease and transplant rejection, Vanderbilt researchers discovered.

By Bill Snyder
November 3, 2020

New treatment for a rare obesity

Diabetes drugs known as GLP-1 receptor agonists, such as exenatide (Byetta), are a promising and safe treatment for a rare form of obesity.

By Bill Snyder
August 13, 2015

Simmons strives to make a difference in children’s lives

Jill Simmons, M.D., encounters medical mysteries that have the makings of a science fiction film or novel.

By Christina Echegaray
September 12, 2013

VU tracking drug’s ability to prevent type 1 diabetes

Vanderbilt’s Eskind Diabetes Clinic has been selected to examine the ability of the drug abatacept to prevent type 1 diabetes (T1D). As part of the TrialNet consortium, Vanderbilt will be one of 14 North American sites observing the effects of the drug in people at high risk to develop T1D.

By VUMC News and Communications